| P50 | author | David Gershenson | Q57167281 |
| | Robert L Coleman | Q88486681 |
| P2093 | author name string | William E Brady | |
| | Kathleen N Moore | |
| | R Wendel Naumann | |
| | Jubilee Brown | |
| P2860 | cites work | Mutational heterogeneity in cancer and the search for new cancer-associated genes | Q24606956 |
| | A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/ Gynecologic Oncology Group Study. | Q30355928 |
| | Comparison of error rates in single-arm versus randomized phase II cancer clinical trials | Q33813448 |
| | Strategy for randomised clinical trials in rare cancers | Q33815608 |
| | Detecting an overall survival benefit that is derived from progression-free survival | Q34063143 |
| | Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial | Q34409341 |
| | Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group | Q34600671 |
| | Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. | Q36371217 |
| | SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm | Q36424039 |
| | Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study | Q36768921 |
| | A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma | Q37432527 |
| | Bayesian statistics in oncology: a guide for the clinical investigator | Q37582338 |
| | Rare cancer trial design: lessons from FDA approvals | Q38020458 |
| | Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma | Q38262332 |
| | Is the NCI MATCH trial a match for gynecologic oncology? | Q38639549 |
| | Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial | Q38654552 |
| | Research methods to change clinical practice for patients with rare cancers. | Q38730151 |
| | Biostatistics primer: what a clinician ought to know: hazard ratios | Q44995023 |
| | Evolution of early phase clinical trials in oncology | Q47816379 |
| | FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper. | Q53095017 |
| | Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer | Q56807699 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | female reproductive system neoplasm | Q56014489 |
| P304 | page(s) | 605-611 | |
| P577 | publication date | 2018-04-24 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | Clinical trial methodology in rare gynecologic tumor research: Strategies for success | |
| P478 | volume | 149 | |